NHS hospitals across England and Wales are introducing a new diagnostic method for bladder cancer that offers greater speed, accuracy and convenience compared with traditional approaches. Clinicians described the Galeas bladder test as a major advance, noting that it relies on a simple urine sample collected at home instead of an invasive hospital procedure. The change is significant for a disease that claims nearly 6,000 lives annually in the UK. Several trusts report higher testing rates because the process is painless and does not require an outpatient visit. Five hospitals have already switched to the test, with Leicester University Hospitals becoming the first English trust to adopt it; at least 16 more are expected to follow by year end. Standard diagnosis uses cystoscopy, in which a tube fitted with a camera is inserted through the urethra to inspect the bladder. Many patients previously declined the examination due to discomfort. The Galeas test analyses DNA from a urine sample for 23 genes linked to bladder cancer. An NHS trial with 964 patients across seven sites in 2024-25 showed 92 percent accuracy, exceeding the 81 percent rate recorded for cystoscopy. The difference arises because manual camera inspection can miss tumours of varying appearance. Developers aim to raise accuracy further during wider rollout. Patients are referred after blood is detected in urine. Consultants at Leicester noted that the new test reduces embarrassment and frees hospital capacity. Early results indicate results are returned within 16 days, meeting the NHS 28-day diagnosis target, and suggest diagnosis may occur up to 50 percent faster than with cystoscopy. The test was developed by researchers at the University of Birmingham. Cancer Research UK, which helped fund early work, said the method could replace some invasive checks and allow earlier detection at GP visits. NHS England officials welcomed the initiative as part of ongoing efforts to diagnose cancer sooner.
